Introduction
Originally sphingolipids were considered to be building blocks of all eukaryotic cell membranes. However, recent advances in our knowledge of sphingolipid metabolism, development of state of the art sphingolipidomic techniques, and knockout of key sphingolipid metabolic enzymes in mice have convincingly illustrated that ceramide, a metabolite of all sphingolipids, is a bioactive lipid that regulates a diverse range of cellular processes including those important for inflammation (reviewed in (1, 2) ). Indeed, several pro-inflammatory cytokines including IL-1 increase ceramide levels in diverse cell types (1) . IL-1 plays an important role in both inflammatory and immune responses to infections or sterile insults and subsequent induction of acute-phase response (APR) (3, 4) . APR is an early innate physiological reaction occurring soon after the onset of infection, trauma, and inflammatory processes resulting in fever, increased vascular permeability, muscle and joint pain, and a variety of metabolic and pathologic changes. The liver is the major organ targeted by IL-1 and members of the IL-6 cytokine family during APR resulting in dramatic increases in synthesis of acute phase proteins (APP) such as alpha-1-acid glycoprotein, C-reactive protein, and serum amyloid-A in humans and mice (5) . and complex sphingolipids derived from ceramide and several new subunits and regulatory proteins that regulate its activity have recently been described (reviewed in (12) ). Extensive studies in yeast have elegantly demonstrated that the ORM1 and ORM2 proteins interact with and negatively regulate SPT (13) (14) (15) (16) (17) (18) . Moreover, it was shown that TORC1 and TORC2 protein kinase complexes are involved in phosphorylation of ORM proteins to adjust sphingolipid synthesis and coordinate cell growth with environmental cues, such as nutrient accessibility and stress (17, 18) . In mammalian cells, the three homologs, ORMDL1-3, have also been implicated in regulation of SPT activity and ceramide biosynthesis (13, (19) (20) (21) . However, in contrast to their yeast orthologs, similar phosphorylations of ORMDL proteins cannot be involved in regulating SPT as they lack the N-terminal phosphorylated region described in yeast ORMs. Moreover, although silencing of expression of all three ORMDLs in cell culture was shown to increase ceramide (13, (20) (21) (22) , not much is known of the functions of the individual endogenous ORMDL proteins in regulation of ceramide levels. Here we determined the functions of ORMDL1-3 in human HepG2 cells, examined changes in their expression levels in response to key pro-inflammatory cytokines important for APR, and studied changes in ORMDL expression and ceramide levels in IL-1-mediated sterile inflammation in mice. 
MATERIALS AND METHODS

Turpentine-induced inflammation
C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, ME). All animal studies were conducted in the Animal Research Core Facility at VCU School of Medicine in accordance with the institutional guidelines. Animals were bred and maintained in a pathogen-free environment and all procedures were approved by the
Quantitative real-time PCR
Total RNA was prepared utilizing TRIzol (Life Technologies). One microgram of RNA was reverse transcribed using the high-capacity cDNA Archive kit (Life Technologies). Premixed primer-probe sets and TaqMan Universal PCR Master Mix (Life Technology) were employed to examine mRNA levels. cDNAs were diluted 10-fold (for target genes) or 100-fold (for GAPDH) and amplified using the CFX Connect RealTime PCR Detection System (BIO-RAD). Gene expression levels were calculated by the ΔΔCt method, normalized to Gapdh expression, and presented as fold of mean values ± SEM.
Western blotting
Cells were lysed in 10 mM Tris (pH 7.4), 150 mM sodium chloride, 1 mM EDTA, 0.5% Nonidet P-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 mM PMSF, and Lipids were extracted from cells and liver tissues. Samples were collected into 13
x 100 mm borosilicate tubes with a Teflon-lined cap (VWR, West Chester, PA). Then 2 ml of CH 3 OH and 1 ml of CHCl 3 were added together with the internal standard cocktail.
The contents were dispersed by sonication at room temperature for 30 s. The single phase mixtures were incubated at 48°C overnight. After cooling, 150 µl of 1 M KOH in CH 3 OH was added and, after brief sonication, incubated in a shaking water bath for 2 h at 37°C to cleave potentially interfering glycerophospholipids. The extracts were brought to neutral pH with 12 µl of glacial acetic acid, centrifuged in a table-top centrifuge, and the supernatants transferred to new tubes. The extracts were reduced to dryness using a speed vac. The dried residues were reconstituted in 0.5 ml of the starting mobile phase solvent for LC-ESI-MS/MS analysis, sonicated for 15 sec, then centrifuged for 5 min before transfer of the clear supernatants to autoinjector vials for analysis.
Sphingolipids were separated by reverse phase HPLC using a Shimadzu Nexera injection (typically 40 µl), the A1/B1 ratio was maintained at 95/5 for 2.25 min, followed by a linear gradient to 100% B1 over 1.5 min, which was held at 100% B1 for 5. For analysis of de novo sphingolipid synthesis, HepG2 cells were transfected with siRNA as above for 48 h, washed and then incubated for 6 h in medium containing tests for experiments consisting of three or more groups (Prism, GraphPad Software, La Jolla, CA, USA). P < 0.01 was considered to be statistically significant. All experiments were repeated at least three times with consistent results. For mouse studies, three to six randomly chosen mice were used per experimental group.
Results
Downregulation of ORMDL3 but not ORMDL1 or 2 increases dihydoceramide
Yeast ORM1 and 2 proteins have been reported to bind to and inhibit SPT, the rate-limiting step in de novo ceramide synthesis (13) (14) (15) (16) (17) (18) , and their human orthologs confirmed that a commercially available anti-ORMDL3 antibody recognized a 17 kDa band corresponding to the molecular weight of ORMDLs (Fig. 1B) . Although simultaneous downregulation of all three ORMDLs reduced the ORMDL protein expression below detectable levels, a significant decrease was not observed with individual knockdowns (Fig. 1B) . This is probably due to the greater than 80% homology between ORMDL1, 2, and 3.
We first examined the effects of knockdown of ORMDLs on levels of dihydroceramides, intermediates in the de novo pathway. Downregulation of ORMDL3, but not ORMDL1 or ORMDL2, dramatically increased levels of dihydroceramides (Fig.   1C ). This increase was especially robust in C16:0, C18:0, C20:0, C22:0, and C24:1 dihydroceramide species (Fig. 1C ). There were also large increases in the same species of monohexosyldihydroceramide ( Fig. 1D ) as well as in C16:0, dihydrosphingomyelin (Fig. 1E ). The effects on dihydrosphingomyelins were likely less dramatic due to the large pool of dihydrosphingomyelins within the cell. Additionally, simultaneous knockdown of all three ORMDL proteins had a stronger effect on increasing dihydroceramides and monohexosyldihydroceramides (Fig. 1C,D ), albeit to a lesser extent, whereas dihydrosphingomyelins were not further increased by simultaneous downregulation of all three ORMDLs (Fig. 1E ).
Effects of downregulation of ORMDLs on ceramide levels
In the de novo sphingolipid biosynthesis pathway, dihydroceramides are direct precursors of ceramides. In agreement with its effect on dihydroceramides, siORMDL3 also significantly increased levels of most ceramide acyl chain species ( Fig. 2A) .
Although siORMDL1 did not increase dihydroceramides (Fig. 1C) , it did cause a small increase in level of the very long chain C24:1 ceramide species ( Fig. 2A) . However, this was not accompanied by significant increases in the levels of further metabolites of ceramide, monohexosylceramide and sphingomyelin (Fig. 2B,C) . In contrast, siORMDL3 caused small elevations of C16:0, C22:0, and C24:0 species of monohexosylceramide and had almost no effects on sphingomyelins (Fig. 2B,C) .
Moreover, consistent with its lack of effect on dihydroceramides, siORMDL2 did not have a reproducible effect on ceramides ( Fig. 2A) , monohexosylceramides (Fig. 2B ), or sphingomyelins ( Fig. 2C) . In contrast to the robust effects on dihydroceramides, downregulation of all three ORMDLs had only minor effects on complex sphingolipid levels compared to downregulation of only ORMDL3 alone.
Effects of downregulation of ORMDLs on sphingoid bases
Downregulation of all three ORMDL isoforms increased levels of cellular dihydrosphingosine (Fig. 3A) , the precursor of dihydroceramides, and also of its phosphorylated form, dihydro-S1P (Fig. 3B) , as well as sphingosine ( Fig. 3C ) and S1P (Fig. 3D ). siORMDL3 alone also increased levels of dihydro-S1P, sphingosine and S1P (Fig. 3) . However, unexpectedly, siORMDL1 also increased levels of sphingosine, even though it had no effect on levels of dihydrosphingosine-containing lipids (Fig. 3) . It should be noted that sphingosine is not an intermediate in the biosynthesis of sphingolipids, but rather a degradation product of ceramide.
Downregulation of ORMDL3 increases de novo sphingolipid synthesis
Given our observed increases in dihydrosphingolipids (Fig. 1 ) and the reported role of ORMDL proteins in regulating de novo sphingolipid synthesis, we directly followed dihydroceramide biosynthesis by pulse labeling cells with [U- 1 and 2, only siORMDL3 increased unlabeled dihydroceramides (Fig. 4D ) as well as dramatically increasing base-only and dual-labeled ceramide species (Fig. 4E,F) .
Inflammatory cytokines important for the acute phase response decrease ORMDL protein and increase dihyroceramides and ceramides
Earlier studies demonstrated that ceramide is elevated during APR (10), the early innate response to infections and inflammation. In addition to activation of neutral sphingomyelinase (27, 28), liver APR induced by LPS led to increased de novo synthesis of ceramide by increasing expression and activity of SPT (11 5B ). Moreover, dihydrosphingosine and sphingosine, as well as S1P, were also increased ( Fig. 5C ). Although as expected, IL-1 and OSM increased transcription of the acute phase protein serum amyloid A1 (SAA1) (Fig. 5D ), no changes were detected in mRNA levels of ORMDL1, ORMDL2, or ORMDL3 (Fig. 5D) . Interestingly, stimulation of HepG2 cells with IL-1 and OSM caused a significant decrease in ORMDL protein detected by immunoblotting (Fig. 5E ), suggesting that this may be due to increased degradation. The decrease in ORMDL protein expression is consistent with the increases in dihydroceramides and ceramides.
Irritant-induced inflammation decreased ORMDL protein expression and increased ceramides and dihydroceramides in the liver
To examine the effect on ORMDLs expression during APR, we used a mouse model of irritant-induced acute inflammation that is IL-1-dependent (4). In this model, s.c. injection of turpentine causes tissue destruction at the site of injection, infiltration of inflammatory cells and production of cytokines, including IL-1 and OSM (23). This is followed by a systemic response and production of APPs in the liver (30) . Indeed, were observed in mRNA levels of any of the ORMDLs as measured by QPCR (Fig. 6A) , turpentine treatment also induced a significant decrease in ORMDL protein levels within 8 h which remained reduced after 24 h (Fig. 6B) . Consistent with this decrease in
ORMDLs, liver levels of dihydroceramides ( Fig. 7A ) and ceramides ( Fig. 7B) were significantly increased by turpentine and generally evenly distributed across all acyl chain species. Although no major changes were observed in levels of dihydrosphingomyelins or sphingomyelins (Fig. 7A,B ), significant increases, especially after 24 h, were observed in some monohexosyldihydroceramide and monohexosylceramide species (Fig. 7A,B) . However, there were no significant changes in sphingoid bases or their phosphorylated forms (Fig. 7C) .
A portion of the de novo generated ceramide in the liver is secreted into blood as components of very-low density lipoproteins (VLDL) and low density lipoproteins (LDL).
Because changes in hepatic SPT activity affect the rate of ceramide secretion (11), we also measured the effects of turpentine treatment on sphingolipid levels in blood. At 8 h following treatment with turpentine, there were only minor effects on levels of dihyroceramides and ceramides (Fig. 8A,B) . However, after 24 h, there were significant increases in dihydroceramides (Fig. 8A ) and more pronounced increases in ceramides, particularly C22:0, C24:1, and C24:0 species (Fig. 8B ). Dihydrosphingomeylins and sphingomyelins (Fig. 8A,B) were not greatly affected by turpentine although there were robust increases after 24 h in monohexosyldihydroceramides and monohexosylceramides (Fig. 8A,B) . At this time point, there were also small increases in blood levels of phosphorylated sphingoid bases (Fig. 8C ).
Discussion
Here we demonstrated that decreasing expression of ORMDL3 in liver cells, but not ORMDL1 or 2, induced a dramatic increase in dihydrosphingosine and It must be noted that we did observe that knockdown of all three ORMDL proteins simultaneously had a stronger effect on levels of dihydrosphingosine and dihydrosphingosine-containing lipids than knockdown of ORMDL3 alone. This also supports the notion that while ORMDL3 is a strong and potentially physiologically relevant control node for regulation of sphingolipid biosynthesis, the three ORMDL proteins may have overlapping functions. As expected from the increased levels of sphingolipids, we observed that decreased ORMDL3 expression increased levels of free sphingoid bases and sphingoid base phosphates and also caused increases in cellular levels of ceramides. Levels of complex sphingolipids were also increased, though to a lesser extent, likely due both to the large pools of these sphingolipids within the cell and the relatively short times of knockdown.
Intriguingly, although ORMDL1 had no effect on dihydrosphingosine or dihydrosphingosine-containing sphingolipids, we found that its downregulation modestly increased levels of sphingosine, S1P, and ceramide. Thus, ORMDL1 may act anti-tubulin to ensure equal transfer and loading and quantified by densitometry (n=3).
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